Benjamin Rengstl

T cell malignancies after CAR T cell therapy in the DESCAR-T registry

Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung

CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.

A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination